Expanded Access Program With Nivolumab to Treat Melanoma

NO_LONGER_AVAILABLE

Conditions studied: Stage III (Unresectable) or Stage IV Advanced Melanoma

In brief

The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.

Key facts

Study ID
NCT02142218
Run by
Bristol-Myers Squibb
Starts
2014-06-01
Expected to finish
2018-05-01
Last updated by the study team
2016-09-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.